Drawing based on the description in the official product monograph. No photo yet.
“10 mg tablets for suspension are white to slightly-yellow, round biconvex 6 mm tablets debossed with "D" on one side and "NVR" on the other”
D NVR pill
Pill with imprint D NVR is white, round, 6 mm and has been identified as Dabrafenib Mesylate 10 mg. It is used for melanoma. It is supplied by Novartis Pharmaceuticals Canada Inc.
Sold in Canada
Dabrafenib Mesylate 10 mg
- Brand
- Tafinlar
- Imprint
- D NVR
- Strength
- 10 mg
- Used for
- Melanoma
- Color
- White
- Shape
- Round
- Size
- 6 mm
- Form
- Tablet for suspension
- Manufacturer
- Novartis Pharmaceuticals Canada Inc
- Drug class
- Cancer medicine (kinase inhibitor)
- Sold in
- Canada
- DIN
- 02540053
Source: Health Canada's Drug Product Database and the official product monograph. Last checked .
Report a mistake
What is Dabrafenib used for?
Dabrafenib is used for melanoma.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma
TAFINLAR® is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma
TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma
TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
BRAF V600E Mutation-Positive Metastatic NSCLC
TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer
TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.
BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
BRAF V600E Mutation-Positive Low-Grade Glioma
TAFINLAR is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
Limitations of Use
- TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.
- TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors.
From the FDA-approved label on DailyMed (published May 21, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows D NVR. The parts can be split between the two sides, so turn the pill over and check both.
- It is white, round, 6 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold in Canada as Tafinlar by Novartis Pharmaceuticals Canada Inc.
In Canada: prescription only.
Ingredients
Active: Dabrafenib (Dabrafenib Mesylate)
Other pills with imprint D NVR
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
par 256 MINOXIDIL 2 1 2
Minoxidil 2.5 mg
White, round, 7 mm
Used for severe high blood pressure and hair loss
-
L1
Colchicine Tablets 0.5 Mg 0.5 mg
White, round, 6 mm
-
C83
Dipyridamole 75 mg
White, round, 6 mm
-
C82
Dipyridamole 50 mg
White, round, 6 mm
-
C81
Dipyridamole 25 mg
White, round, 6 mm
-
AA 91
Albuterol 2 mg
White, round, 6 mm
Used for asthma and bronchial spasm
Other Dabrafenib pills
- GSTEW 50mg Dabrafenib 50 mg Red, oval, 18 mm Used for melanoma
- GSLHF 75mg Dabrafenib 75 mg Red, oval, 20 mm Used for melanoma
- No picture yet DIN 02409607 Dabrafenib Mesylate 50 mg Tafinlar, Capsule, sold in Canada Used for melanoma
- No picture yet DIN 02409615 Dabrafenib Mesylate 75 mg Tafinlar, Capsule, sold in Canada Used for melanoma